Vimarsana
Biggest News Aggregation in the World

Page 29 - Allo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Allo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Allo Today - Breaking & Trending Today

Three home runs power Yankees over Twins - Vimarsana News

Three home runs power Yankees over Twins

Aaron Judge, Giancarlo Stanton and Anthony Rizzo each homered, and the New York Yankees pulled away for a 10-4 win over the Minnesota Twins on Tuesday night in

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of "Buy" by Brokerages - Vimarsana News

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of "Buy" by Brokerages

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) have earned a consensus recommendation of “Buy” from the fifteen ratings firms that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12-month price […]

Robert W. Baird Begins Coverage on Allogene Therapeutics (NASDAQ:ALLO) - Vimarsana News

Robert W. Baird Begins Coverage on Allogene Therapeutics (NASDAQ:ALLO)

Research analysts at Robert W. Baird started coverage on shares of Allogene Therapeutics (NASDAQ:ALLO – Get Rating) in a research report issued on Thursday, The Fly reports. The brokerage set a “neutral” rating on the stock. Several other equities research analysts also recently issued reports on the company. Raymond James dropped their price objective on […]

Zacks: Analysts Expect Allogene Therapeutics, Inc. (NASDAQ:ALLO) Will Post Earnings of -$0.61 Per Share - Vimarsana News

Zacks: Analysts Expect Allogene Therapeutics, Inc. (NASDAQ:ALLO) Will Post Earnings of -$0.61 Per Share

Analysts expect Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) to report ($0.61) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Allogene Therapeutics’ earnings. The highest EPS estimate is ($0.59) and the lowest is ($0.67). Allogene Therapeutics reported earnings per share of ($0.53) in the same quarter […]

Allogene Therapeutics (NASDAQ:ALLO) & SAB Biotherapeutics (NASDAQ:SABS) Head to Head Contrast - Vimarsana News

Allogene Therapeutics (NASDAQ:ALLO) & SAB Biotherapeutics (NASDAQ:SABS) Head to Head Contrast

Allogene Therapeutics (NASDAQ:ALLO – Get Rating) and SAB Biotherapeutics (NASDAQ:SABS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership. Risk & Volatility Allogene Therapeutics has a beta of […]